

ALEXION PHARMACEUTICALS INC  
Form 8-K  
June 15, 2004

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) June 14, 2004**

---

**ALEXION PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

<b>Delaware</b> (State or Other	<b>0-27756</b> (Commission	<b>13-3648318</b> (IRS Employer
Jurisdiction of Incorporation)	File Number)	Identification No.)
<b>352 Knotter Drive, Cheshire, CT</b> (Address of Principal Executive Offices)		<b>06410</b> (Zip Code)

**Registrant's telephone number, including area code: (203) 272-2596**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)



**Item 5. Other Events and Regulation FD Disclosure.**

On June 14, 2004, the Company announced that they and their collaboration partner for pexelizumab, Procter & Gamble Pharmaceuticals, Inc., have received written confirmation from the U.S. Food and Drug Administration indicating agreement with the protocols for two independent pivotal Phase III trials of the investigational drug pexelizumab. A copy of the press release issued by the Company relating thereto is filed herewith as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

**(c) Exhibits.**

99.1 Press Release dated June 14, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: June 15, 2004

By: /s/ Thomas I.H. Dubin  
Name: Thomas I.H. Dubin  
Title: Vice President and General Counsel